Slide 1: Cover letter to stock exchanges
October 20, 2023 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q2 FY24
Investor Presentation Q2 FY24
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q2 FY24 Highlights
Q2 FY24 | Highlights “I am pleased to share that we continue to deliver remarkable growth, propelled by a robust GPL business and steady external API business. Geographically, regulated Dr. Yasir Rawjee markets including the US, Europe, LATAM and India continue to spearhead our growth. Managing Dire
Slide 5: Q2 & H1 FY24 Performance
Q2 & H1 FY24 Performance Strong growth with stable margins PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 16.9% 23.6% 23.4% 21.0% 19.4% 33.7% 33.7% 19.9% 1,464 30.2% 11.94 29.0% 6,213 28.1% 1,355 11.05 5,785 2,093 5,407 1,95
Slide 6: P&L Highlights Q2 & H1 FY24
P&L Highlights | Q2 & H1 FY24 Particulars (In ₹ Millions) Q2 FY24 Q1 FY24 QoQ Q2 FY23 YoY H1 FY24 H1 FY23 YoY Revenue from Operations 5,954 5,785 2.9% 5,093 16.9% 11,738 9,992 17.5% Gross Profit 3,223 3,304 -2.5% 2,693 19.7% 6,527 5,303 23.1% Gross Profit (%) 54.1% 57.1% 52.9% 55.6% 53.1% Other Inco
Slide 7: Strong Returns Indicators
Strong Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 40% 202 36% 176 171 34% 36% 3.3 3.4 152 170 31% 2.9 2.9 98 102 104 99 89 152 136 120 116 126 -48 -43 -53 -60 FY20 FY21 FY22 FY23 H1 FY24 FY20 FY21 FY22 FY23 H1 FY24 -67 • ROICE is tracking at ~36% – Higher capital employed dr
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 31.0% 20.4% 19.7% 31.5% 31.4% CAGR 11.4% 29.7% 20.8% 18.6% 21,612 21,232 38.1
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance Generic & CDMO business
Segment Performance | Generic & CDMO business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Rev enu e In ₹ Milli o n s ) 568 5,428 5,299 464 5,042 4,799 309 279 4,533 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 • Generic API revenues in Q2FY24 increased by 19.7%
Slide 11: Segment Performance GPL vs. External
Segment Performance | GPL vs. External External GPL GPL External (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 37.2% 33.9% 33.5% 74.0% 2,309 29.0% 26.0% 1,964 71.0% 3,904 1,594 66.1% 1,338 66.5% 3,814 3,821 3,755 62.8% Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q2 FY23 Q3
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 18% 19% 22% 20% 25% 29% 34% 32% 39% 39% 8% 5% Others 6% 3% Emerging 7% 5% 6% 4% 3% Pain Management Markets 4% 17% 14% 18% 12% Diabetes 82% 81% 80% 15% 75% 78% CNS Regulated Markets CVS 42% 40% 43% 36% 38% Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 489 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 95 122 157 10+ 18 125+ 10+ 50+ 21 76 (Brazil) India – Mix of Regulated Number of Number of customers As of Sep 30, 2023 Reg
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend North (In ₹ Milli o n s) Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 37 31 4 21 10 33 136 As % to Sales CNS 36 22 8 13 2 14 95 3.1% Diabetes 9 5 - 8 - 12 34 3.0% Pain Management 1 2 - 4 1 8 16 2.7% Others 74 35 6 30 8 55 2
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity Last USFDA Mahape, Navi Mumbai Location Approvals (Jun-23) Inspection Date R&D for new product development and complex USFDA, MHRA (UK), FIMEA (Finland), molecule
Slide 17: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Status & Planned Capacity Timelines 208 KL (Under Construction) FY24 Brownfield API / Intermediate Ankleshwar Planned addition of 280KL-300KL FY25-FY26 Brownfield API Dahej Planned addition of 220KL-240KL FY24-FY26 CTE recei
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RAHUL THAKUR Email: Diwakar.Pingle@in.ey.com Email: Rahul.Thakur@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA House, 47